SCHEMBL538533

SCHEMBL538533

Fc1cccc(CNc2nc3c4c(n[nH]c4n2)CCN3)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.42
PAK4 O96013 2/20 0.41
PLK4 O00444 1/20 0.41
CYP1A2 P05177 2/20 0.40
GRM5 P41594 1/20 0.40
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
ADORA2B P29275 2/20 0.36
ADORA2A P29274 1/20 0.36
PDE2A O00408 1/20 0.36
MAP4K4 O95819 2/20 0.36
GSK3B P49841 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537750 0.86 HTT (0.39) APPHTR2CROCK1CDC7MAPT
SCHEMBL2812440 0.81 HSD17B10 (0.42) CYP1A2CLK4CLK2DYRK1ADYRK1B
SCHEMBL2813861 0.80 GRK6 (0.38) HTR2CAURKA
SCHEMBL537732 0.79 CETP (0.40) APPHTR2CHTR2BADORA2BADORA2A
SCHEMBL16915834 0.71 APP (0.44) APPPAK4CYP1A2GRM5KDM5A
SCHEMBL16916787 0.71 GRM5 (0.44) APPPAK4CYP1A2GRM5HTR2C
SCHEMBL538534 0.70 APP (0.41) APPPAK4PLK4ADORA2BADORA2A
SCHEMBL16916684 0.67 VCP (0.46) APPPAK4KDM5AKDM4CKDM5B
SCHEMBL17741901 0.66 APP (0.56) APPPAK4PLK4ADORA2BADORA2A
SCHEMBL16915884 0.65 VCP (0.52) APPHTR2CHTR2BCDK2CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP claimed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO claimed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 APP 3167/4885PAK4 104/4885PLK4 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.